Leads Biolabs receives CSRC filing notice to convert 45.61 million unlisted shares into H shares

Bulletin Express05-08

Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) announced that it has obtained a “Notification of filing on the ‘Full Circulation’ of Unlisted Shares” from the China Securities Regulatory Commission (CSRC), dated 27 April 2026. The filing allows the company to proceed with its H-share full-circulation programme, under which 44.39 million unlisted shares held by 23 shareholders will be converted into H shares. The conversion and listing must be completed within 12 months of the filing notice.

On 8 May 2026, Leads Biolabs submitted additional filing materials to the CSRC to include a further 1.22 million unlisted shares held by one shareholder. In total, 45.61 million shares are slated for conversion and subsequent listing on The Stock Exchange of Hong Kong.

According to the company’s articles of association, the conversion does not require another shareholders’ meeting. Final completion remains subject to the approval procedures of the Hong Kong Stock Exchange and other relevant regulators.

The board cautions shareholders and potential investors to exercise care when dealing in the company’s shares until the conversion and listing process is finalised. Leads Biolabs will provide further updates in accordance with Hong Kong Listing Rules.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1176407072?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-08 20:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1176407072","market":"us","top_or_hot":-1,"title":"Leads Biolabs receives CSRC filing notice to convert 45.61 million unlisted shares into H shares","media":"Bulletin Express","content":"<p>Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) announced that it has obtained a “Notification of filing on the ‘Full Circulation’ of Unlisted Shares” from the China Securities Regulatory Commission (CSRC), dated 27 April 2026. The filing allows the company to proceed with its H-share full-circulation programme, under which 44.39 million unlisted shares held by 23 shareholders will be converted into H shares. The conversion and listing must be completed within 12 months of the filing notice.</p>\n<p>On 8 May 2026, Leads Biolabs submitted additional filing materials to the CSRC to include a further 1.22 million unlisted shares held by one shareholder. In total, 45.61 million shares are slated for conversion and subsequent listing on The Stock Exchange of Hong Kong.</p>\n<p>According to the company’s articles of association, the conversion does not require another shareholders’ meeting. Final completion remains subject to the approval procedures of the Hong Kong Stock Exchange and other relevant regulators.</p>\n<p>The board cautions shareholders and potential investors to exercise care when dealing in the company’s shares until the conversion and listing process is finalised. Leads Biolabs will provide further updates in accordance with Hong Kong Listing Rules.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Leads Biolabs receives CSRC filing notice to convert 45.61 million unlisted shares into H shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLeads Biolabs receives CSRC filing notice to convert 45.61 million unlisted shares into H shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-08 20:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) announced that it has obtained a “Notification of filing on the ‘Full Circulation’ of Unlisted Shares” from the China Securities Regulatory Commission (CSRC), dated 27 April 2026. The filing allows the company to proceed with its H-share full-circulation programme, under which 44.39 million unlisted shares held by 23 shareholders will be converted into H shares. The conversion and listing must be completed within 12 months of the filing notice.</p>\n<p>On 8 May 2026, Leads Biolabs submitted additional filing materials to the CSRC to include a further 1.22 million unlisted shares held by one shareholder. In total, 45.61 million shares are slated for conversion and subsequent listing on The Stock Exchange of Hong Kong.</p>\n<p>According to the company’s articles of association, the conversion does not require another shareholders’ meeting. Final completion remains subject to the approval procedures of the Hong Kong Stock Exchange and other relevant regulators.</p>\n<p>The board cautions shareholders and potential investors to exercise care when dealing in the company’s shares until the conversion and listing process is finalised. Leads Biolabs will provide further updates in accordance with Hong Kong Listing Rules.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09887","symbol_name":"维立志博-B","start_time":0,"source_url":"","article_id":"1176407072","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1176407072","pubTimestamp":1778243104,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) announced that it has obtained a “Notification of filing on the ‘Full Circulation’ of Unlisted Shares” from the China Securities Regulatory Commission...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09887":"维立志博-B"},"translate_title":"Leads Biolabs收到证监会备案通知4561万股非上市股份转H股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09887":1},"content_text":"Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) announced that it has obtained a “Notification of filing on the ‘Full Circulation’ of Unlisted Shares” from the China Securities Regulatory Commission (CSRC), dated 27 April 2026. The filing allows the company to proceed with its H-share full-circulation programme, under which 44.39 million unlisted shares held by 23 shareholders will be converted into H shares. The conversion and listing must be completed within 12 months of the filing notice.\nOn 8 May 2026, Leads Biolabs submitted additional filing materials to the CSRC to include a further 1.22 million unlisted shares held by one shareholder. In total, 45.61 million shares are slated for conversion and subsequent listing on The Stock Exchange of Hong Kong.\nAccording to the company’s articles of association, the conversion does not require another shareholders’ meeting. Final completion remains subject to the approval procedures of the Hong Kong Stock Exchange and other relevant regulators.\nThe board cautions shareholders and potential investors to exercise care when dealing in the company’s shares until the conversion and listing process is finalised. Leads Biolabs will provide further updates in accordance with Hong Kong Listing Rules.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1176407072","isCrawlerRequest":true}